Carcinoma, Squamous Cell of Head and Neck Clinical Trial
Official title:
Open-label, Single Arm, Multi-centre, Phase II Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin With Superficial and Interstitial Laser Light Application in Patients With Recurrent Head and Neck Cancer
Verified date | February 2022 |
Source | PCI Biotech AS |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the efficacy and safety of Amphinex induced PCI of bleomycin ('PC-A11') with superficial and/or interstitial laser light application in patients with recurrent SCCHN.
Status | Terminated |
Enrollment | 26 |
Est. completion date | January 2016 |
Est. primary completion date | August 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Study eligibility reviewed and approved by interdisciplinary hospital team. 2. Age minimum 18 years. 3. Histologically or cytological confirmed diagnosis of recurrent or metastatic SCCHN considered unsuitable for surgery and radiotherapy (patients with distant or regional metastatic disease may be eligible if local palliation is needed) 4. Performance status (WHO scale/ECOG) = 1. 5. At least one measurable target lesion at baseline. 6. Local disease including margin (0.5 cm) treatable with superficial and/or interstitial laser light application (for superficial lesions: entire tumour assessable for laser light application/interstitial treatment: insertion of implants feasible) 7. Estimated life expectancy of at least 12 weeks. 8. Written informed consent. Exclusion criteria: Prior Treatment: 1. Local treatment of their SCCHN by surgery within the previous 4 weeks or by radiation within the previous 3 months. 2. Previous treatment with systemic chemotherapy for their SCCHN within the last 4 weeks 3. Previous treatment with Photodynamic Therapy within the last 6 months. 4. Prior treatment with bleomycin. 5. Prior treatment with PC-A11. 6. Toxicities incurred as a result of previous anticancer therapy (radiation therapy, chemotherapy, or surgery) which did not resolve to = grade 2. Current Treatment: 7. Current or recent (within 30 days of first study treatment) treatment with another investigational drug or participation in another investigational study. 8. Other concurrent anticancer therapies. 9. Treatment with a medicinal product with known or potential drug-drug interaction with bleomycin or Amphinex. Haematology, coagulation and biochemistry: 10. Inadequate bone marrow function: Absolute Neutrophil Count (ANC): < 1.5 x 109/L, or platelet count <100 x 109/L or haemoglobin < 6 mmol/L. 11. Inadequate liver function, defined as: Serum (total) bilirubin > 2 x the Upper Limit of Normal (ULN) for the institution. Aspartate Amino Transferase (ASAT) or Alanine Amino Transferase (ALAT) > 2.5 x ULN. Alkaline phosphatase levels > 2.5 x ULN. 12. Glomerular filtration rate (GFR) < 30ml/min. 13. Clinical significant electrolyte abnormalities (Potassium, Magnesium, Phosphate that is greater than CTCAE grade 3 for both low and high values) Other: 14. Tumours known or suspected to be eroding into a major blood vessel, e.g. carotid artery (interna and /or communis) in or adjacent to the illumination site (minimum distance between tumour tissue and critical structure should be 0.5 cm). 15. Nasopharyngeal carcinoma. 16. Conditions contraindicated for bleomycin treatment (current lung infection, severely impaired pulmonary function) excluded by lung function test (either formal lung function test for patients able to undertake such assessment, or a suitable opinion by an appropriately trained Respiratory / Anaesthetic Clinical Specialist). 17. Conditions that worsen when exposed to light (including porphyria). 18. Inability to undergo CT or MRI. 19. Pregnancy or lactation (female patients with childbearing potential). Serum pregnancy test to be performed within 7 days prior to study PC-A11 treatment start, or within 14 days followed by a confirmatory urine pregnancy test within 7 days prior to study treatment start. 20. For female patients of childbearing potential (defined as < 2 years after last menstruation and not surgically sterile) and male patients who are not surgically sterile or with female partners of childbearing potential: absence of highly effective method of contraception resulting in a low failure rate (i.e. less than 1% per year). These methods of contraception according to the note for guidance on non-clinical safety studies for the conduct of human trials for pharmaceuticals (CPMP/ICH/286/95, modification) include consistent and correct use of hormone containing implants and injectables, combined oral contraceptives, hormone containing intrauterine devices, surgical sterilization, sexual abstinence and vasectomy. Note: Abstinence is only acceptable as true abstinence: when this is in line with the preferred and usual lifestyle of the subject, periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. 21. Planned surgery, endoscopic examination or dental treatment in first 30 days after PC-A11 treatment. 22. Co-existing ophthalmic disease likely to require slit-lamp examination within the first 90 days after PC-A11 treatment. 23. Congestive heart failure New York Heart Association (NYHA) Class III and IV. Cardiac arrhythmias (except for atrioventricular block type I, Mobitz type II, and Wenckebach type) signs and symptoms of relevant cardiovascular disease. 24. Known allergy or sensitivity to photosensitisers. 25. Ataxia telangiectasia 26. Concomitant malignant disease, with exception of adequately treated basal cell carcinoma, squamous cell carcinoma or other non-melanomatous skin cancer, or in-situ carcinoma of the uterine cervix. 27. Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, physical examination or laboratory findings) that may interfere with the planned PC-A11 treatment, affect patient compliance or place the patient at high risk from treatment-related complications. |
Country | Name | City | State |
---|---|---|---|
France | Centre Alexis Vautrin (CAV)-Nancy Université | Nancy | |
France | CHU de Nantes Hôtel Dieu | Nantes | Nantes Cedex 1 |
Germany | Charité Comprehensive Cancer Center | Berlin | |
Germany | Universitätsklinikum Essen | Essen | |
Germany | Universitätsklinikum Schleswig-Holstein | Lübeck | Schleswig-Holstein |
Germany | Ludwig Maximilian University Munich | München | |
Lithuania | Institute of Oncology, Vilnius University | Vilnius | |
Netherlands | The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital | Amsterdam | |
Poland | Szpital Specjalistyczny w Brzozowie | Brzozów | |
United Kingdom | University College London Hospital | London |
Lead Sponsor | Collaborator |
---|---|
PCI Biotech AS |
France, Germany, Lithuania, Netherlands, Poland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Evaluation of biomarkers obtained from tumour tissue and blood samples | The run-in part and expansion part secondary outcome measure | 12 months | |
Other | Evaluation of skin photosensitivity | The run-in part and expansion part secondary outcome measure | 3 months | |
Other | Evaluation of local tumour responses by volumetric measurements. | The run-in part and expansion part secondary outcome measure | 12 months | |
Other | Evaluation of fluorescence of tumour tissue | The run-in part and expansion part secondary outcome measure | Day 4 | |
Other | Evaluation of pain | Scored by a visual analogue score (VAS) | 12 months | |
Primary | Dose-limiting toxicities (DLT) | The 'run-in part' primary endpoint | 3 months | |
Primary | The proportion of patients with non-progressive local disease at 6 months | The expansion part primary endpoint | 6 months | |
Secondary | Pharmacokinetics of 'PC-A11' in plasma | The run-in part and expansion part secondary endpoint | 3 months | |
Secondary | The proportion of patients with non-progressive local disease at 3 months | The run-in part and expansion part secondary endpoint | 12 months | |
Secondary | Proportion of patients with adverse events | The run-in part and expansion part safety endpoint | 12 months | |
Secondary | Progression free survival | The run-in part and expansion part secondary outcome measure | 12 months | |
Secondary | QoL using EORTC Quality of Life Questionnaire (QLQ)-C30 version 3.0 and QLQ-H&N35 | The run-in part and expansion part secondary outcome measures | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02113878 -
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
|
Phase 1 | |
Active, not recruiting |
NCT03291002 -
Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC
|
Phase 1 | |
Terminated |
NCT02277184 -
Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 1 | |
Completed |
NCT01080066 -
A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)
|
N/A | |
Completed |
NCT02585973 -
Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC
|
Phase 1 | |
Completed |
NCT01836029 -
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
Active, not recruiting |
NCT03715946 -
Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03088059 -
Biomarker-based Study in R/M SCCHN
|
Phase 2 | |
Recruiting |
NCT06003231 -
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
|
Phase 2 | |
Terminated |
NCT02438995 -
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
|
Phase 1 | |
Completed |
NCT02242916 -
State of the Art Photon Therapy Versus Particle Therapy for Recurrent Head & Neck Tumors; a Planning Study
|
N/A | |
Recruiting |
NCT01876693 -
A Prospective Study of Prophylactic Gastrostomy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy
|
N/A | |
Terminated |
NCT02655068 -
Phase III Trial of PET/CT vs. CTSurveilance for Head and Neck Cancer
|
Phase 3 | |
Active, not recruiting |
NCT03509012 -
Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02296684 -
Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Active, not recruiting |
NCT03799744 -
Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma
|
Phase 1 | |
Completed |
NCT03109158 -
NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
|
Phase 1/Phase 2 | |
Recruiting |
NCT03485209 -
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
|
Phase 2 | |
Completed |
NCT01307267 -
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
|
Phase 1 | |
Terminated |
NCT02822482 -
Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss
|
Phase 1/Phase 2 |